Products Officially Approved in China
2026

Iron‑deficiency anaemia
(2007-2026)
For the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to alleviate symptoms associated with exercise
Q2 2026

2025

Approved indication in Mainland China: Acute otitis externa
Approved indication in Hong Kong: Acute otitis media in patients with tympanostomy tubes
Q1 2025
Extensive‑Stage Small‑Cell Lung Cancer (ES‑SCLC)
Q3 2025

2024

Allergic rhinitis, allergic dermatitis and allergic bronchial asthma
Q2 2024
Q1 2024


Acne vulgaris
Q1 2024
Recurrent or metastatic cervical cancer
Q1 2024

2023

Psoriasis
Q3 2023
Delivery system of Nitric Oxide for Inhalation
Q2 2023


Used in combination with chemotherapy for Hodgkin’s lymphoma in adult
Q2 2023
Agitation associated with schizophrenia or bipolar I disorder in adults
Q2 2023

2022

Hypertension
Q4 2022
Extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS)
Q3 2022


Hypoxic respiratory failure associated with pulmonary hypertension
Q2 2022
2021
lmmunosuppression in rental
transplantation
Q2 2021


Granules
Urea cycle disorders
Q2 2021
Injection
Prevent deep vein thrombosis, unstable angina & myocardial infarction
Q1 2021

2020

Depressive disorders
Q4 2020
Urinary tract infections & chronic bronchitis
Q2 2020


Pulmonary arterial hypertension
Q1 2020
2019
Chemotherapy-induced nausea & vomiting
2019


Hypertension
2019
Lactic acid bacteria blended powder (Solid drink)
(2019-2022)
2017

Urinary incontinence
2017
2014
Pulmonary arterial hypertension
(2014 – 2019)
2013
Carnitine deficiency
(2013-2022)
2012
Hypertension
2008

Corneal ulcer burns & keratitis
2008
2007
Iron‑deficiency anaemia
2007

2006

Hemostasis
2006
2003
Carnitine deficiency
(2003-2022)
2001

Cervical erosion & herpes
2001
1998
Formation of blood & deep vein thrombosis
1998

1997
Cerebral ischemic stroke











